Abstract
Adipose tissue has evolved into a highly specialized tissue for storing energy in the form of triglycerides (TGs, also called triacylglycerols, or “fat”). It is heterogeneous in cellular composition, location, and function – reflecting its complex role in normal physiology and disease [1]. It is comprised not only of different types of adipocytes (ranging from white to brown) but also other non-adipocyte cell types (such as stromal vascular and immune cells) to form a true multicellular organ [2]. Unlike other organs, adipose tissue is distributed throughout the body where it exhibits location-specific properties. Furthermore, its functions extend well beyond its role in fat storage to a variety of other processes necessary for physiological homeostasis including energy homeostasis, immune homeostasis, and reproductive function [3]. The heterogeneity of adipose tissue is reflected by the variety of clinical disorders that result from adipose tissue dysfunction [4, 5]. Indeed, both adipose tissue excess (obesity) and deficiency (lipodystrophy) result in profound physiological impairments that promote the metabolic syndrome (see chapter “Metabolic syndrome”) and cardiovascular disease (see chapter “Atherosclerotic heart disease”). Adipose tissue dysfunction or excess also contributes to a myriad of other diseases affecting virtually all organ systems including liver disease, i.e., fatty liver and cirrhosis (see chapter “Cirrhosis”); kidney disease, e.g., diabetic and hypertensive nephropathy (see chapters “Diabetes mellitus” and “Hypertension”); pulmonary disease, e.g., sleep apnea; musculoskeletal disease, i.e., arthritis (see chapters “Osteoarthritis” and “Rheumatoid arthritis”) and back pain; reproductive disease, i.e., infertility; psychological disease, i.e., depression (see chapter “Major depressive disorder”); and even cancer (see chapter “Overview” under the part “Cancer”) [6]. Thus, adipose tissue is not simply an inert tissue for storing fat, but a highly dynamic tissue required for health and survival. By understanding the unique characteristics of adipose tissue, can we begin to exploit its complexities to treat or prevent disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gesta S, Tseng YH, Kahn CR (2007) Developmental origin of fat: tracking obesity to its source. Cell 131:242–256
Cinti S (2012) The adipose organ at a glance. Dis Model Mech 5:588–594
Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556
Garg A (2011) Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab 96:3313–3325
Herbst KL (2012) Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol Sin 33:155–172
Malnick SD, Knobler H (2006) The medical complications of obesity. QJM 99:565–579
Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360:1509–1517
Wu J, Cohen P, Spiegelman BM (2013) Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev 27:234–250
Bickel PE, Tansey JT, Welte MA (2009) PAT proteins, an ancient family of lipid droplet proteins that regulate cellular lipid stores. Biochim Biophys Acta 1791:419–440
Karastergiou K, Mohamed-Ali V (2010) The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 318:69–78
Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, Wang S, Fortier M, Greenberg AS, Obin MS (2005) Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347–2355
Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Ann Rev Immunol 29:415–445
Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, Hamnvik OP, Koniaris A (2011) Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 301:E567–E584
Turer AT, Scherer PE (2012) Adiponectin: mechanistic insights and clinical implications. Diabetologia 55:2319–2326
Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697–738
Flier JS (2004) Obesity wars: molecular progress confronts an expanding epidemic. Cell 116:337–350
Malik VS, Willett WC, Hu FB (2013) Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol 9:13–27
O'Rahilly S (2009) Human genetics illuminates the paths to metabolic disease. Nature 462:307–314
Magkos F, Yannakoulia M, Chan JL, Mantzoros CS (2009) Management of the metabolic syndrome and type 2 diabetes through lifestyle modification. Annu Rev Nutr 29:223–256
Grun F, Blumberg B (2009) Endocrine disrupters as obesogens. Mol Cell Endocrinol 304:19–29
McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, Benca RM, Biggio J, Boggiano MM, Eisenmann JC, Elobeid M, Fontaine KR, Gluckman P, Hanlon EC, Katzmarzyk P, Pietrobelli A, Redden DT, Ruden DM, Wang C, Waterland RA, Wright SM, Allison DB (2009) Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr 49:868–913
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Wien
About this chapter
Cite this chapter
Schoiswohl, G., Aljammal, J., Kershaw, E.E. (2014). Overview. In: Lammert, E., Zeeb, M. (eds) Metabolism of Human Diseases. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0715-7_29
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0715-7_29
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0714-0
Online ISBN: 978-3-7091-0715-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)